Just hit the wires.
Trying to decide?
NVAX will be bought the question is by who and for how much, and how soon.
Why wouldn't they? They may have a majority stake, but that doesn't preclude another interested party approaching FMI. Seems Roche has a specific interest in FMI that they'd like to protect.
Lead in results. My point is that the lead in results from Ignite 2 have such a wide margin of superiority over Levofloxacin, that it would seem impossible not to maintain that results into the Pivotal portion coming soon. Even if the pivotal portion results weren't as positive, I don't see 20 point superiority gap closing. So primary endpoint should be easy to obtain, and even the secondary endpoint looks promising.
70.8 vs 52.2 Responder Rate (Ervacycline vs Levofloxacin)
75.0 vs 56.5 Microbial Response (Ervacycline vs Levofloxacin)
That's a wide margin of superiority IMO. Particularly in a cUTI. Thoughts?
Anyone hearing rumblings of this? Something like 13.6M remaining shares they have to take between $45-50.
Didn't realize LGND was this grossly over valued. Especially when Biotech's are getting crushed. $55-60 is a better pps.
I think it's going to be difficult to achieve the Primary endpoint in the ProHema Phase 2 trial in adults. The Interim data on engraftment did not appear overwhelming. I believe only nine patients had engraftment ahead of the median time of historical controls which they defined as 26 days for MAC and 21 for RIC. Checking some articles on prior studies those controls seemed on the high end, which seems to bias the study a bit. On a positive note ProHema does seem to have a positive effect on suppressing CMV reactivation, but that's only a secondary endpoint of the study.
I could see a scenario where they fail to meet their primary endpoint, but meet their secondary endpoints. I think that would have a negative impact on the stock, so I'm cautious. Thoughts?
Anyone else concerned with yesterday's close?
Love them wall street games...
And we all know how that turned out. Both have active clinical trials targeting Waldenstrom's. Baker Bros knows this as well. Remember the days when PCYC was $4?
But why? Why are big names buying so much IDRA? I don't get it. The only thing I can think of is - Crohn's Disease. If IDRA's TOL Inhibitors can be used to effectively treat Crohn's the market potential would be incredible. Maybe they know something we don't. But that's the only theory I have. Any others?
What do these guys know that we don't? Comments welcome?
Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
BAKER BROS. ADVISORS LP 03/31/2015 6,965,432 5,337,260 327.81 25,006
BROADFIN CAPITAL, LLC 03/31/2015 5,663,845 2,138,145 60.65 20,333
FMR LLC 03/31/2015 4,575,770 680,500 17.47 16,427
BLACKROCK FUND ADVISORS 03/31/2015 2,428,564 739,353 43.77 8,719
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A. 03/31/2015 1,942,504 1,042,904 115.93 6,974
PALO ALTO INVESTORS, LLC 03/31/2015 1,170,248 1,170,248 New 4,201
HEALTHCOR MANAGEMENT, L.P. 03/31/2015 1,165,786 357,494 44.23 4,185
ALYESKA INVESTMENT GROUP, L.P. 03/31/2015 1,005,067 1,005,067 New 3,608
Read more: http://www.nasdaq.com/symbol/idra/institutional-holdings#ixzz3cbOraGo2